Subscribe now

Health

Merck in court over osteoporosis drug

19 April 2006

THE drugs giant Merck may need to hire yet more lawyers. Already facing lawsuits from thousands of patients who blame their heart disease on the painkiller Vioxx, Merck is now battling claims that its osteoporosis drug Fosamax can erode the jawbones.

Tim O’Brien, an attorney in Pensacola, Florida, has filed a suit on behalf of 250 patients who developed osteonecrosis of the jaw after taking Fosamax. In this condition, diminished blood supply causes bone to die.

Osteonecrosis of the jaw is a rare side effect of bisphosphonates, the class of drugs that includes Fosamax, particularly when people have had dental…

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers.

Sign up

To continue reading, subscribe today with our introductory offers

Piano Exit Overlay Banner Mobile Piano Exit Overlay Banner Desktop